Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma
Tomoharu Yamada(The University of Tokyo), Hayato Nakagawa(RIKEN Center for Integrative Medical Sciences), Naoto Fujiwara(The University of Texas Southwestern Medical Center), Shigeyuki Kurosaki(University of Tokyo Hospital), Yuki Matsushita(University of Tokyo Hospital), Kazuhiko Koike(Kanto Central Hospital), Tatsuya Minami(The University of Tokyo), Mitsuhiro Fujishiro(Bunkyo University), Kiyoshi Hasegawa(Bunkyo University), Junichi Arita(Akita University), Akihiko Ichida(The University of Tokyo), Ryosuke Tateishi(Bunkyo University), T. Nakatsuka(The University of Osaka), Naoto Kubota(Keio University)
Cited by 28
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k